copper-lysine complex | 21512-99-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: copper-lysine complex
• 英文别名: Cu(lysine)₂；Bis(L-lysinato)copper；copper;(2S)-2,6-diaminohexanoate
• CAS: 21512-99-2
• 化学式: C₁₂H₂₆CuN₄O₄
• 分子量: 353.909
• InChiKey: XMLZGFYSGKWISJ-MDTVQASCSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -3.62
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  184
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  copper-lysine complex 在 盐酸 、 platinum on activated charcoal 、 氢气 、 edetate disodium 、 碳酸氢钠 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 68.33h， 生成 Bz-Lys-OMe
  参考文献：
  名称：

  Novel Aminopeptidase N Inhibitors with Improved Antitumor Activities

  摘要：

  一系列氨肽酶N（APN）抑制剂的设计与合成得以完成。通过酶抑制、对接和抗增殖研究来评估所得到的分子。分子D15在APN酶抑制试验中表现最佳，其IC50值为10.9微摩尔。对接研究发现，分子D9与D15在APN活性位点的结合模式得以预测，发现疏水性和氢键相互作用在配体与受体结合中发挥了关键作用。与先前的C7相比，多个分子如D9、D14和D15在抑制HL-60、ES-2、A549和PLC细胞系的生长方面表现出显著提升的活性。

  DOI：

  10.2174/1570180812666150611190608
• 作为产物：
  描述：

  copper(ll) sulfate pentahydrate 、 DL-赖氨酸 以 not given 为溶剂， 生成 copper-lysine complex
  参考文献：
  名称：

  草酸二水合物分解铜-氨基酸复合物

  摘要：

  提出了一种通过草酸二水合物作为铜螯合剂合成一些侧链保护氨基酸的简便方法。氨基酸络合物中的铜与...

  DOI：

  10.1139/v2012-032

文献信息

• ENERGY-EFFICIENT SOLVENT-FREE METHOD FOR PRODUCING METAL CHELATES
  申请人：TECHNISCHE UNIVERSITAT CLAUSTHAL

  公开号：US20210309674A1

  公开（公告）日：2021-10-07

  The invention relates to a method for producing, amongst other things, amino-acid and/or hydroxycarboxylic-acid metal chelates, a solvent-free mixture of at least one metal oxide, metal hydroxide, metal carbonate or oxalate, and the solid organic acid is subjected to intensive mechanical stress. According to the invention, this is done in that the reaction partners are introduced in particle form into a fluid stream of a fluid-bed countercurrent mill operating without grinding elements, wherein mechanical activation of at least one of the reaction partners is effected by collision processes within a reaction chamber formed in a region of the fluid stream, and a solid body reaction to form the metal chelate is triggered. The novel method operates very energy-efficiently and with a high specific yield. It leads to a product having compact particles in the small, single-digit micrometer range having a comparatively narrow particle size distribution and a large surface. The product is homogenous and very pure. Thermal loading or decomposition of the organic chelate ligands, in particular of the amino acids, is likewise avoided, as are contaminants from milling and grinding element abrasion.

  该发明涉及一种制备氨基酸和/或羟基羧酸金属螯合物的方法，其中包括无溶剂的至少一种金属氧化物、金属氢氧化物、金属碳酸盐或草酸盐的混合物，以及将固体有机酸受到强烈机械应力。根据该发明，通过将反应物以颗粒形式引入无磨粒元素运行的流化床逆流磨中，其中至少一个反应物的机械活化通过在流体流动区域内形成的反应室内的碰撞过程来实现，并触发形成金属螯合物的固体体反应。这种新方法运行非常节能，并具有高特定产量。它导致产物具有在小型、个位数微米范围内的致密颗粒，具有相对较窄的颗粒大小分布和大表面。该产品是均匀且非常纯净的。同时也避免了有机螯合配体（特别是氨基酸）的热负荷或分解，以及来自磨削和磨粒元素磨损的污染物。
• New polymer materials for contact lens applications
  申请人：CIS Pharma AG

  公开号：US20200283560A1

  公开（公告）日：2020-09-10

  The present invention relates to copolymers made from a polymerization mixture comprising (a) one or more polymerizable monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, (b) one or more not-functionalized side chain-linked amino acids, (c) one or more functionalized side chain-linked amino acids, (d) a free radical initiator and, optionally, (e) a chain-transfer-agent. It also relates to block copolymers comprising the same monomers. The invention also encompasses silicone hydrogel contact lenses coated with or comprising the latter copolymers and block copolymers as well methods for introducing the copolymers and block copolymers into silicone hydrogel contact lenses.

  本发明涉及由聚合混合物制成的共聚物，所述聚合混合物包括（a）一种或多种可聚合单体，该单体被表征为至少具有一个乙烯基团且不含氨基酸残基，（b）一种或多种未功能化的侧链连接的氨基酸，（c）一种或多种功能化的侧链连接的氨基酸，（d）自由基引发剂，以及可选地，（e）链转移剂。还涉及包含相同单体的嵌段共聚物。该发明还涵盖涂有或包含后述共聚物和嵌段共聚物的硅水凝胶隐形眼镜，以及将这些共聚物和嵌段共聚物引入硅水凝胶隐形眼镜的方法。
• [EN] BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS<br/>[FR] SUPPORTS DE MÉDICAMENT POLYMÈRES BIOCOMPATIBLES PERMETTANT L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：CIS PHARMA AG

  公开号：WO2021084087A1

  公开（公告）日：2021-05-06

  The present disclosure relates to the delivery of multiple copies of a payload molecule such as an active agent or a chelating agent capable of capturing an active agent, using as a carrier for their delivery a biocompatible copolymer comprising side chain-linked amino acids functionalized at their alpha-amino group by a reactive azide moiety by means of which the payload molecules are coupled to the copolymer. The copolymer is typically further functionalized to contain a single copy of a cell type- or tissue type-specific targeting moiety.

  本公开涉及使用生物相容性共聚物作为载体，传递多个剂量分子副本，如活性剂或能够捕获活性剂的螯合剂。这些共聚物包含通过其α-氨基团上的反应性叠氮基团功能化的侧链连接氨基酸，通过这种方式，荷载分子与共聚物耦合。通常，这种共聚物进一步功能化，以包含细胞类型或组织类型特异性靶向基团的单个副本。
• PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING
  申请人：Vision Global Holdings Ltd.

  公开号：US20140335018A1

  公开（公告）日：2014-11-13

  The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

  本发明提供了一种含有基于血红蛋白的治疗药物的药物组合物，用于治疗癌症。血红蛋白部分可以靶向癌细胞，治疗部分（即活性剂/治疗药物）可以高效地杀死癌细胞。本发明中使用的基于血红蛋白的治疗药物可用于治疗各种癌症，如胰腺癌、白血病、头颈癌、结直肠癌、肺癌、乳腺癌、肝癌、鼻咽癌、食管癌、前列腺癌、胃癌和脑癌。该组合物可单独使用或与其他治疗剂（如化疗剂）结合使用，对癌症治疗产生协同作用，抑制转移和/或减少复发。目前申请的基于血红蛋白的5FU-双染料共轭物和/或基于血红蛋白的5FU-单染料共轭物也可用于活细胞成像和诊断成像。
• [EN] METHOD AND MOLECULES<br/>[FR] MÉTHODE ET MOLÉCULES
  申请人：MEDIMMUNE LLC

  公开号：WO2018218093A1

  公开（公告）日：2018-11-29

  The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.

  本发明提供了一种生物共轭方法和其中使用的化合物。该生物共轭方法包括将含有第一不饱和官能团的生物分子与包含第二不饱和官能团的荷载物质共轭的步骤，其中第一和第二不饱和官能团互补，使得通过 Diels-Alder 反应发生官能团之间的结合，形成一个环己烯环。